<unk>  is used for the treatment of cystic fibrosis in people having one of several specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein: E56K, G178R, S549R, K1060T, G1244E, P67L, E193K, G551D, A1067T, S1251N, R74W, L206W, G551S, G1069R, S1255P, D110E, R347H, D579G, R1070Q, D1270N, D110H, R352Q, S945L, R1070W, G1349D, R117C, A455E, S977F, F1074L, R117H, S549N, F1052V, D1152H.<unk>  is also included in a combination product, lumacaftor/ivacaftor, in a single pill, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR.<unk>  is also included in the combination product tezacaftor/ivacaftor with<unk>  sold as Symdeko and as Symkevi. Symdeko is indicated to treat people aged six and older who have two copies of the F508del mutation in CFTR. Symkevi is indicated in a combination regimen with<unk>  150 mg tablets for the treatment of people with cystic fibrosis (CF) aged twelve years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.<unk>  is available in a combination product with elexacaftor and tezacaftor called Trikafta for the treatment of people with cystic fibrosis who have the F508del mutation or other mutations.
Ivacaftor
Lifitegrast
Roxadustat
Arformoterol
Formoterol
Zafirlukast
Lumacaftor/ivacaftor
Fluticasone